- Home
- BFRI
BFRI
Biofrontera Inc.
as 12-23-2024 4:00pm EST
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | WOBURN |
| Market Cap: | 6.2M | IPO Year: | 2021 |
| Target Price: | $7.00 | AVG Volume (30 days): | 990.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $3.90 | Next Earning Date: | 11-13-2024 |
| Revenue: | $35,358,000 | Revenue Growth: | 5.17% |
| Revenue Growth (this year): | 17.69% | Revenue Growth (next year): | 19.71% |
Latest Biofrontera Inc. News
BFRI Breaking Stock News: Dive into BFRI Ticker-Specific Updates for Smart Investing
GlobeNewswire
13 hours ago
Biofrontera Inc. Announces 100 RhodoLED® XL Machines Now Placed in US Market
ACCESSWIRE
20 days ago
Biofrontera Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference
GlobeNewswire
a month ago
Biofrontera Inc. Closes a $4.2 Million Senior Secured Convertible Note
GuruFocus.com
a month ago
Biofrontera Inc (BFRI) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst Revenue ...
Zacks
a month ago
Biofrontera Inc. (BFRI) Reports Q3 Loss, Lags Revenue Estimates
GlobeNewswire
a month ago
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
ACCESSWIRE
2 months ago
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
GlobeNewswire
2 months ago
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
Compare BFRI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BFRI Biofrontera Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.